Auriga

A report from Auriga reiterates its Buy rating and lowers its price target form $23 to $21 on Globe Specialty Metals (NASDAQ: GSM). The report states, “Nonetheless, we remain confident in the company's fundamental drivers and growth initiatives. While GSM is not immune from macro risks, we...

A report from Auriga reiterates its Buy rating and raises its price target from $71 to $74 on Weight Watchers International (NYSE: WTW). The report states, “Weight Watchers reported strong results for its third quarter, reflecting continued consumer support for its PointsPlus plan, which was...

Auriga has raised the price target on Weight Watchers (NYSE: WTW) from $71 to $74 and maintains its Buy rating.

Auriga has raised the price target on Globe Specialty Metals (NASDAQ: GSM) from $21 to $23 and maintains its Buy rating.

Auriga is out with a research report on Fusion-IO (NYSE: FIO) after it reported earnings, and it has a Sell rating and a $18 price target on shares. In a note to clients, Auriga writes, "We reiterate our SELL rating following a very strong earnings release driven primarily by upside spending at...

Auriga is out with a research report on MEMC Electronic Materials, Inc. (NYSE: WFR) and it has a Hold rating and a $5 price target on shares. In a note to clients, Auriga writes, "At $5.78 WFR trades at ~11.3x our C2012 non-GAAP EPS estimate of $0.51, and ~5.7x our C2013 EPS estimate of $1.01. To...

Auriga is out with a research report on Nutrisystem (NASDAQ: NTRI) and it has a Buy rating and is lowering its price target to $17 from $19. In a note to clients, Auriga writes, "Nutrisystem reported 3Q11 results that were below our expectations as well as consensus. During 3Q11, Nutrisystem was...

Auriga has lowered the price target on Nutrisystem (NASDAQ: NTRI) from $19 to $17 and maintains its Buy rating.

Auriga has lowered the price target on MEMC Electronic Materials (NYSE: WFR) From $7 to $5 and maintains its Hold rating.

Boston Beer (NYSE: SAM) reported earnings last night that "hopped" past Wall Street analysts. It also raised its 2011 earnings guidance significantly, sending shares soaring this morning. The Boston-based brewer of over 25 styles of beer reported third quarter earnings of $1.19 per share on $134....

A report from Auriga reiterates its Hold rating and $35 price target on Thoratec (NASDAQ: THOR). The report states, “As worries around HTWR's HVAD recede, HTWR appears to capturing most of the incremental market growth. Further, we expect the 3Q results will once again move questions surrounding...

A report from Auriga reiterates its Buy rating and $24 price target on Myriad Genetics (NASDAQ: MYGN). The report states, “MYGN's other tests grew 20% Y/Y. Overall, MYGN continues to execute and put up very solid results despite some economic headwinds (office visits were down 4% in the quarter)....

A report from Auriga reiterates its Buy rating and $7 price target on ISTA Pharmaceuticals (NASDAQ: ISTA). The report states, “The company's revenue came in at $41.4 million vs. consensus of $43.3 million, and our estimate of $42 million. EPS came in at $0.09 vs. the consensus and our estimate of...

A report from Auriga reiterates its Buy rating and lowers its price target from $39 to $37 on Cavium Networks (NASDAQ: CAVM). The report states, “the company reported in-line 3Q11 but its 4Q11 guidance fell well short of our/consensus expectations on weak macro trends, inventory correction and...

Auriga has lowered the price target on Cavium Networks (NASDAQ: CAVM) from $39 to $37 and maintains its Buy rating.